ADBiotech Co

ADBiotech Co Stock-Based Compensation

The Stock-Based Compensation (SBC) of ADBiotech Co (179530.KQ) as of Nov 22, 2026 is 81.52 M KRW. In the previous year, Stock-Based Compensation (SBC) was 97.85 M KRW — a change of -16.70% (lower).

Stock-Based Compensation

81.52 MKRW

YoY

-16.70%

Last updated:

Stock-Based Compensation (SBC) of ADBiotech Co is 2025 81.52 M KRW. Stock-Based Compensation (SBC) of ADBiotech Co was 2024 97.85 M KRW. It decreases by -16.70% lower compared to the previous year.

The ADBiotech Co Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2020
116.51 M KRW
Jan 1, 2021
74.91 M KRW
Jan 1, 2022
172.90 M KRW
Jan 1, 2023
80.28 M KRW
Jan 1, 2024
97.85 M KRW
Jan 1, 2025
81.52 M KRW
The ADBiotech Co Stock-Based Compensation history
YEARStock-Based CompensationYoY
81.52 MKRW-16.70%
97.85 MKRW+21.89%
80.28 MKRW-53.57%
172.90 MKRW+130.81%
74.91 MKRW-35.71%
116.51 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ADBiotech Co Stock analysis

What does ADBiotech Co do? ADbiotech Co., Ltd. generates revenue by manufacturing and selling chemical products across two distinct business segments. The Veterinary Medicine segment focuses on the production of antibiotics, anticoccidial agents, antimicrobial agents, nervous system agents, and synthetic antibacterial agents for use in pharmaceuticals and stockbreeding. This division serves customers in the animal health sector by providing essential medical compounds for livestock and other animals. The Supplementary Feed segment complements the core operations by manufacturing and selling functional supplementary feeds and other related products. This segment targets the stockbreeding and fisheries industries, offering nutritional solutions to enhance animal health and productivity. By combining these two segments, ADBiotech Co., Ltd. delivers a comprehensive range of chemical and feed-based solutions to its clients in Chuncheon, Gangwon-Do. ADBiotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ADBiotech Co stock

Stock-Based Compensation (SBC) of ADBiotech Co is 81.52 M KRW in 2025.

Stock-Based Compensation (SBC) of ADBiotech Co changed from 97.85 M KRW to 81.52 M KRW, representing a -16.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) ADBiotech Co since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s ADBiotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ADBiotech Co

All Key Metrics — ADBiotech Co